SRR1389036
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.418
- KRAS_SIGNALING_DN+0.416
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.364
- INTERFERON_ALPHA_RESPONSE+0.351
- INFLAMMATORY_RESPONSE+0.329
- INTERFERON_GAMMA_RESPONSE+0.299
- BILE_ACID_METABOLISM+0.297
- ANGIOGENESIS+0.274
- XENOBIOTIC_METABOLISM+0.270
- ESTROGEN_RESPONSE_LATE+0.265
Top 10 suppressed
- MYC_TARGETS_V1-0.620
- DNA_REPAIR-0.504
- PROTEIN_SECRETION-0.499
- OXIDATIVE_PHOSPHORYLATION-0.494
- MYC_TARGETS_V2-0.492
- UNFOLDED_PROTEIN_RESPONSE-0.480
- MTORC1_SIGNALING-0.417
- E2F_TARGETS-0.371
- PI3K_AKT_MTOR_SIGNALING-0.338
- G2M_CHECKPOINT-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR817775 | GTEX | — | 0.966 |
| 2 | SRR1330699 | GTEX | — | 0.964 |
| 3 | SRR1374115 | GTEX | — | 0.963 |
| 4 | SRR1332856 | GTEX | — | 0.958 |
| 5 | SRR1417070 | GTEX | — | 0.956 |
| 6 | SRR1455698 | GTEX | — | 0.951 |
| 7 | SRR1375616 | GTEX | — | 0.950 |
| 8 | SRR1468141 | GTEX | — | 0.944 |
| 9 | SRR1444559 | GTEX | — | 0.944 |
| 10 | SRR1321552 | GTEX | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.418 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.416 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.364 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.351 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.329 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.299 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.297 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.274 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.265 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.244 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.226 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.213 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.212 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.207 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.166 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.157 | Inavolisib | — uncovered |
| MYOGENESIS | 0.143 | Inavolisib | — uncovered |
| COMPLEMENT | 0.136 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.107 | Idelalisib | — uncovered |